Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1730 (116th)

Cancer Drug Parity Act of 2019

referredUnited States· United States Congress· EN

Introduced

13 March 2019

Last action

14 March 2019 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Higgins, Brian [D-NY-26], Rep. Guthrie, Brett [R-KY-2], Rep. Matsui, Doris O. [D-CA-7], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Kilmer, Derek [D-WA-6], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. King, Peter T. [R-NY-2], Rep. Nadler, Jerrold [D-NY-12], Rep. DeFazio, Peter A. [D-OR-4], Rep. Hastings, Alcee L. [D-FL-20], Rep. Olson, Pete [R-TX-22], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Hurd, Will [R-TX-23], Rep. Bera, Ami [D-CA-6], Rep. Cole, Tom [R-OK-4], Rep. Khanna, Ro [D-CA-17], Rep. McCaul, Michael T. [R-TX-10], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Latta, Robert E. [R-OH-5], Rep. Moulton, Seth [D-MA-6], Rep. Gianforte, Greg [R-MT-At Large], Rep. Pingree, Chellie [D-ME-1], Rep. Stefanik, Elise M. [R-NY-21], Rep. Rice, Kathleen M. [D-NY-4], Paul Cook, Rep. Price, David E. [D-NC-4], Rep. Marchant, Kenny [R-TX-24], Rep. Cohen, Steve [D-TN-9], Rep. Bucshon, Larry [R-IN-8], Rep. Raskin, Jamie [D-MD-8], Rep. Walberg, Tim [R-MI-5], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Hice, Jody B. [R-GA-10], Rep. Garamendi, John [D-CA-8], Rep. Bost, Mike [R-IL-12], Rep. Davis, Rodney [R-IL-13], Rep. Clarke, Yvette D. [D-NY-9], Rep. Wittman, Robert J. [R-VA-1], Rep. Roybal-Allard, Lucille [D-CA-40], Rep. Mast, Brian J. [R-FL-21], Rep. Case, Ed [D-HI-1], Rep. Tipton, Scott R. [R-CO-3], Rep. Sarbanes, John P. [D-MD-3], Rep. Posey, Bill [R-FL-8], Rep. Rush, Bobby L. [D-IL-1], Rep. Young, Don [R-AK-At Large], Rep. Kennedy, Joseph P., III [D-MA-4], Rep. Guest, Michael [R-MS-3]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Cancer Drug Parity Act of 2019 This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 13 March 2019

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 13 March 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 13 March 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 14 March 2019

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 13 March 2019

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 13 March 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 13 March 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 172 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.